Alivas Inc.

Alivas Inc. is a Tokyo-based company specializing in the development of innovative medical devices targeting refractory chronic constipation, providing alternative treatments for patients unresponsive to traditional therapies. Founded in 2017 and headquartered in Tokyo, Japan, Alivas Inc. focuses on the creation of medical devices for chronic constipation treatment.

Tomoyuki Tajima serves as both the founder and CEO. The company has completed three deals, with the most recent funding round being a Series B raising JPY 348. 900 million on April 17, 2023, from investors including DBJ Capital, Gemseki Investment, Global Brain, and MedVenture Partners. The company has achieved a total valuation of JPY 1738.

235 million. Alivas Inc. develops innovative medical devices specifically designed to treat refractory chronic constipation, impacting over 10 million people in Japan. Their primary product is a novel therapeutic device, developed in collaboration with institutions such as Stanford University and the University of Tokyo, intended for patients resistant to conventional pharmacological treatments.

The company is currently focusing on the Japanese market, which has a significant demand for effective solutions. Alivas Inc. has raised approximately JPY 348. 900 million through its Series B funding round, engaging several notable investors, including MedVenture Partners, DBJ Capital, Gemseki, and Global Brain.

The company operates under a business-to-business (B2B) model, forming partnerships with healthcare providers to integrate its medical devices into clinical settings through direct sales agreements with hospitals and clinics. In April 2023, Alivas Inc. secured JPY 348. 900 million in a Series B funding round aimed at product development.

The company plans to introduce new products that address chronic constipation and expand into additional markets beyond Japan. Specific target regions for expansion have yet to be detailed, but the recent funding will be dedicated to product development initiatives.